Navigation Links
Sanofi New Drug Application for Lixisenatide Accepted for Review by FDA
Date:2/19/2013

PARIS, Feb. 19, 2013 /PRNewswire/ -- Sanofi (EURONEXT : SAN and NYSE : SNY) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA) for lixisenatide, the first once-daily prandial GLP-1 receptor agonist for the treatment of adults with type 2 diabetes mellitus. The acceptance of the lixisenatide NDA filing follows the February 1, 2013, European Commission approval of lixisenatide in the European Union.

(Logo: http://photos.prnewswire.com/prnh/20110624/NY25833LOGO

"We are very pleased to announce the FDA acceptance of our submission for lixisenatide in the U.S.," said Pierre Chancel, Senior Vice President, Global Diabetes at Sanofi. "This important milestone is the result of our company's continuing worldwide effort to meet the needs of people living with diabetes, and we look forward to working with the FDA during the review process."

The NDA submission for lixisenatide is based on results from the GetGoal clinical program, which showed that lixisenatide demonstrated significant reductions in HbA1c, a pronounced post-prandial glucose (PPG)-lowering effect and a beneficial effect on body weight in adult patients with type 2 diabetes. GetGoal results also showed that lixisenatide had a favorable safety and tolerability profile in most patients, with mild and transient nausea and vomiting, the most common adverse events observed in the GLP-1 receptor agonist class, and a limited risk of hypoglycemia.

The international GetGoal program included 11 clinical trials involving more than 5,000 patients with type 2 diabetes, with a large number of patients studied to evaluate a GLP-1 receptor agonist in combination with basal insulin (1,250 patients treated with lixisenatide or placebo in three trials).The addition of lixisenatide to basal
'/>"/>

SOURCE Sanofi
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Sanofi Pasteur Presents Pediatric Data on Investigational Quadrivalent Influenza Vaccine
2. Sanofi US Launches Collaborate Activate Innovation Challenge
3. Sanofi Pasteur to add 2D barcode to six more vaccines
4. Sanofi and Regeneron Announce Publication of Phase 2 Results with LDL Cholesterol-Lowering PCSK9 Antibody in the New England Journal of Medicine
5. Sanofi and Regeneron Announce Patient Enrollment in Cardiovascular Outcomes Trial with Antibody to PCSK9 for Hypercholesterolemia
6. Sanofi and T1D Exchange to Launch Worldwide Study to Investigate Factors for Optimal Care for Young People with Diabetes
7. Sanofi Donates $500,000 to Hurricane Sandy for Immediate and Long-Term Relief Efforts
8. Phase II Trial of Sanofi JAK2 Inhibitor in Myelofibrosis Met Primary Endpoint
9. Sanofi Launches Breakthrough Technology for Cardiovascular and Vascular Surgery Procedures
10. Zacks Bull and Bear of the Day Highlights: Smithfield Foods, Logitech International, Sanofi, Isis Pharmaceuticals and Aegerion Pharmaceuticals
11. Zogenix Submits New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Zohydro™ for Treatment of Chronic Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , September 18, 2014 ... Markets ( http://www.researchandmarkets.com/research/f9nkkh/sugar_alcohols ) has announced the addition ... Business Report"  report to their offering.  ... analyzes the worldwide markets for Sugar Alcohols ... Segments: Food & Confectionery, Pharmaceuticals, Cosmetics, Oral-Care ...
(Date:9/18/2014)... , Sept. 18, 2014   MacPractice,s MacPractice ... Edition Complete EHR certification, which designates that the software ... Stage 1 and Stage 2 Meaningful Use measures required ... Reinvestment Act (ARRA).  MacPractice MD MU version 5.0 was ... , an Office of the National Coordinator-Authorized Certification Body ...
(Date:9/18/2014)... Texas , Sept. 18, 2014  Casen Buswell has ... and muscles to harden.  His case is one of only ... the world.  The only hospital in the United ... the world, offering treatment with the dual wave-length laser, is ... San Antonio . Using a laser available in ...
Breaking Medicine Technology:Sugar Alcohols - Global Strategic Business Report 201 2Sugar Alcohols - Global Strategic Business Report 201 3MacPractice MD MU Achieves ONC HIT 2014 Edition Complete EHR Certification from ICSA Labs 2MacPractice MD MU Achieves ONC HIT 2014 Edition Complete EHR Certification from ICSA Labs 3MacPractice MD MU Achieves ONC HIT 2014 Edition Complete EHR Certification from ICSA Labs 4MacPractice MD MU Achieves ONC HIT 2014 Edition Complete EHR Certification from ICSA Labs 5Methodist Children's Hospital In San Antonio, TX Only Hospital In The U.S. Treating Rare Vascular Condition With Dual Wave-Length Laser 2
(Date:9/18/2014)... Study after study has proven it true: exercise is ... Pennsylvania scientists suggests that exercise may have an added ... performed in a mouse model of melanoma, found that ... alone. , Joseph Libonati, an associate professor in ... of Innovative and Translational Nursing Research, was the senior ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 TayganPoint ... announced today that President and co-founder John Cassimatis ... Innovation Award Winners for 2014, recognizing the region’s ... as an emerging executive of the year. , ... and life sciences that continue to shape the ...
(Date:9/18/2014)... Ben Quirk, CEO of Quirk Healthcare ... Award by the Savannah Science Seminar in recognition for ... the nation and especially in Savannah. , “I am ... “The Savannah Science Seminar is an amazing program that ... have gone through the program,” he added. Eleventh graders ...
(Date:9/18/2014)... A group of international scientists have developed a new ... here . , The Wildlife Conservation Society (WCS)-led ... Tropical Diseases , describes the use of fecal samples ... have been exposed to the virus. This represents a ... can potentially change the way Ebola virus is studied ...
(Date:9/18/2014)... 18, 2014) The National Institutes of Health (NIH) ... four-year, $1.3 million grant to the Los Angeles Biomedical ... and development of a vaccine to protect patients from ... Staphylococcus aureus (MRSA). , The National Institute ... awarded the grant to LA BioMed infectious disease specialists ...
Breaking Medicine News(10 mins):Health News:Exercise boosts tumor-fighting ability of chemotherapy, Penn team finds 2Health News:TayganPoint Executive Receives Prestigious Award from Philadelphia Business Journal 2Health News:Quirk Awarded the Alex Ormond, Jr. Leadership Award by the Savannah Science Seminar 2Health News:Research yields a game changer for improving understanding of Ebola and great apes 2Health News:Research yields a game changer for improving understanding of Ebola and great apes 3Health News:LA BioMed receives NIH grant to study vaccine for hospital-acquired infections 2
... Bottom Line Results by Bringing Previously Unmanaged Areas of Spending ... N.C., June 18 SciQuest , Inc., ... Cincinnati Children,s Hospital Medical Center and ... are among the many well-known organizations that are radically reducing ...
... other warm weather ailments , , SAN ANTONIO, June 18 ... to help pet owners provide a lifetime of care for their ... aware this summer about the dangers of heat exposure. Pet emergency ... the summer months. Dogs and cats of all breeds are sensitive ...
... Practices as First Step in Cancer Care Reform , ... Davis (D-AL), Steve Israel (D-NY) and Mary Jo Kilroy (D-OH) ... Act of 2009. H.R. 2872 is a bill ... & Medicaid Services (CMS) to implement the Quality Cancer ...
... with 30% drop in hours spent together, report finds , ... parents are now spending more hours huddled alone around computer ... time families spend together. , That,s according to a new ... as group has fallen by nearly a third between 2005 ...
... a global leader in food safety and sanitation solutions, ... is safer to store, handle, and use than products ... formulated with generally recognized as safe (GRAS) ingredients, Chemstar ... Commitment(TM) to create products that are environmentally friendly. ...
... scientists are among a multinational collaborative group to have ... European Union. The research will focus on ... common to all solid tumours. Hypoxia causes a ... resistant to radiotherapy and most forms of chemotherapy; as ...
Cached Medicine News:Health News:Healthcare Organizations Rely on SciQuest To Optimize Supply Chains and Generate Savings 2Health News:Healthcare Organizations Rely on SciQuest To Optimize Supply Chains and Generate Savings 3Health News:Healthcare Organizations Rely on SciQuest To Optimize Supply Chains and Generate Savings 4Health News:Healthcare Organizations Rely on SciQuest To Optimize Supply Chains and Generate Savings 5Health News:Protect Your Pets During the Dog (and Cat) Days of Summer 2Health News:Protect Your Pets During the Dog (and Cat) Days of Summer 3Health News:House Bill to Provide Cancer Patients With Solution for Quality Cancer Care Within an Equitable Medicare Model 2Health News:House Bill to Provide Cancer Patients With Solution for Quality Cancer Care Within an Equitable Medicare Model 3Health News:House Bill to Provide Cancer Patients With Solution for Quality Cancer Care Within an Equitable Medicare Model 4Health News:Surging Internet Use Cutting Into Family Time 2Health News:Surging Internet Use Cutting Into Family Time 3Health News:$16.8 million study will breathe new life into cancer battle 2
Specially designed wider jaws to help split soft nucleus, cross action, round handle, maximum opening 2.8 mm....
Specially designed wider jaws to help split soft nucleus, cross action, round handle, maximum opening 2.8 mm....
Cross action, round handle, maximum opening 2.8 mm....
Small pupil irrigating nucleus chopper, wedge-shaped inferior edge with, blunt tip and front notch, for engaging the iris, 0.6 mm dual sideports, 20 gauge....
Medicine Products: